\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{A cohort study of COVID-19 infection in pediatric oncology patients and
the utility of remdesivir treatment}



\author[1]{Rina Yue Ling Ong}%
\author[1]{Valerie Xue Fen Seah}%
\author[1]{Chia-Yin Chong}%
\author[1]{Koh Cheng Thoon}%
\author[1]{Natalie Woon Hui Tan}%
\author[1]{Jiahui Li}%
\author[1]{Karen Donceras Nadua}%
\author[1]{Shui Yen Soh}%
\author[1]{Michaela Su-Fern  Seng}%
\author[1]{Thi Ngoc Anh Pham}%
\author[1]{Chee Fu Yung}%
\author[1]{Kai-Qian Kam}%
\affil[1]{KK Women's and Children's Hospital}%


\vspace{-1em}



  
  \date{May 27, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
\textbf{Introduction} Pediatric oncology patients are reportedly at risk
for progression to severe Coronavirus disease-2019 (COVID-19) infection.
Data on the safety and clinical effectiveness of remdesivir in children
with cancer remains scarce. The main aims of this study were to describe
COVID-19 infection in this cohort and to evaluate the utility of
remdesivir treatment in terms of the time to viral clearance and its
safety profile. \textbf{Methods} This was a retrospective observational
cohort study of pediatric oncology patients [?]18 years of age with
SARS-CoV-2 polymerase chain reaction (PCR) confirmed infection. Patients
were admitted to KK Women's and Children's Hospital from 1
\textsuperscript{st} November 2021 to 31 \textsuperscript{st} March
2022. Clinical data, investigations and laboratory tests results were
collected. \textbf{Results} Eighteen patients were included. Median age
was 6.5 years (IQR: 4.64 -- 9.83), and there were 13 males (72.2\%). The
immunosuppressive status of the cohort was: severe (n = 3, 22.2\%),
moderate (n = 9, 50.0\%) and low (5, 27.8\%). All patients had mild
COVID-19 infection, and there were no COVID-19 attributed deaths.
Remdesivir was initiated in four patients. We did not detect any benefit
in terms of time to viral clearance or SARS-CoV2 PCR cycle threshold [?]25
between the treated versus non-treated groups. Remdesivir was well
tolerated with no safety concerns. \textbf{Conclusion} Our cohort of
immunocompromised pediatric oncology patients all had mild clinical
COVID-19 with no directly attributable morbidity and mortality. In four
patients, treatment with remdesivir was safe but did not lead to early
viral clearance.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`COVIDPAEDSONCO_PBC.docx`  available at \url{https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment}

\textbf{Hosted file}

\verb`COVIDPAEDSONCO_Figures.docx`  available at \url{https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment}

\textbf{Hosted file}

\verb`COVIDPAEDSONCO_Tables.docx`  available at \url{https://authorea.com/users/518156/articles/592424-a-cohort-study-of-covid-19-infection-in-pediatric-oncology-patients-and-the-utility-of-remdesivir-treatment}

\selectlanguage{english}
\FloatBarrier
\end{document}

